OBJECTIVE: To describe the characteristics and health effects of adolescent (age 13-19 years) prescription drug abuse and misuse using the Researched Abuse Diversion and Addiction-Related Surveillance (RADARS(®)) System. METHOD: Secondary analysis of data collected from RADARS System participating poison centers was performed. Data for all intentional exposures from 2007 through 2009 were used to describe adolescent prescription opioid (oxycodone, fentanyl, hydrocodone, hydromorphone, morphine, methadone, buprenorphine, and tramadol) and stimulant (methylphenidate and amphetamines) exposures. RESULTS: A total of 16,209 intentional adolescent exposures to prescription drugs were identified, 68% to opioids and 32% to stimulants. The mean age was 16.6 years (SD ± 1.7 years). Slightly more than half (52.4%) of drug mentions involved females. The five most frequently misused or abused drugs were hydrocodone (32%), amphetamines (18%), oxycodone (15%), methylphenidate (14%), and tramadol (11%). Of all exposures, 38% were classified as suspected suicidal. Of adolescents who intentionally exposed themselves to prescription drugs, 30% were treated in a health care facility, 2,792 of whom were admitted to the hospital, including 1,293 to the intensive care unit. A total of 17.2% of intentional exposures were associated with no effect, 38.9% minor effects, 23.3% moderate effects, 3.6% major effects, and 0.1% were associated with death. Oxycodone and methadone were associated with the most deaths. No deaths were associated with exposures to stimulants. CONCLUSIONS: Prescription drug misuse and abuse poses an important health problem and results in thousands of hospitalizations of adolescents per year. Further work is needed to develop focused interventions and educational programs to prevent prescription drug abuse and misuse by adolescents.
OBJECTIVE: To describe the characteristics and health effects of adolescent (age 13-19 years) prescription drug abuse and misuse using the Researched Abuse Diversion and Addiction-Related Surveillance (RADARS(®)) System. METHOD: Secondary analysis of data collected from RADARS System participating poison centers was performed. Data for all intentional exposures from 2007 through 2009 were used to describe adolescent prescription opioid (oxycodone, fentanyl, hydrocodone, hydromorphone, morphine, methadone, buprenorphine, and tramadol) and stimulant (methylphenidate and amphetamines) exposures. RESULTS: A total of 16,209 intentional adolescent exposures to prescription drugs were identified, 68% to opioids and 32% to stimulants. The mean age was 16.6 years (SD ± 1.7 years). Slightly more than half (52.4%) of drug mentions involved females. The five most frequently misused or abused drugs were hydrocodone (32%), amphetamines (18%), oxycodone (15%), methylphenidate (14%), and tramadol (11%). Of all exposures, 38% were classified as suspected suicidal. Of adolescents who intentionally exposed themselves to prescription drugs, 30% were treated in a health care facility, 2,792 of whom were admitted to the hospital, including 1,293 to the intensive care unit. A total of 17.2% of intentional exposures were associated with no effect, 38.9% minor effects, 23.3% moderate effects, 3.6% major effects, and 0.1% were associated with death. Oxycodone and methadone were associated with the most deaths. No deaths were associated with exposures to stimulants. CONCLUSIONS: Prescription drug misuse and abuse poses an important health problem and results in thousands of hospitalizations of adolescents per year. Further work is needed to develop focused interventions and educational programs to prevent prescription drug abuse and misuse by adolescents.
Authors: Theodore J Cicero; Richard C Dart; James A Inciardi; George E Woody; Sidney Schnoll; Alvaro Muñoz Journal: Pain Med Date: 2007-03 Impact factor: 3.750
Authors: Danice K Eaton; Laura Kann; Steve Kinchen; Shari Shanklin; James Ross; Joseph Hawkins; William A Harris; Richard Lowry; Tim McManus; David Chyen; Connie Lim; Nancy D Brener; Howell Wechsler Journal: MMWR Surveill Summ Date: 2008-06-06
Authors: Lisa A Marsch; Sarah K Moore; Jacob T Borodovsky; Ramon Solhkhah; Gary J Badger; Shelby Semino; Kate Jarrett; Kathleen DiGangi Condon; Kate Rossettie; Phillip Vincent; Neda Hajizadeh; Elizabeth Ducat Journal: Addiction Date: 2016-04-21 Impact factor: 6.526
Authors: David S Festinger; Karen L Dugosh; Nicolle Clements; Anna B Flynn; Mathea Falco; A Thomas McLellan; Amelia M Arria Journal: J Child Adolesc Subst Abuse Date: 2016-05-26
Authors: Y Zhang; A J Brownstein; M Buonora; K Niikura; A Ho; J Correa da Rosa; M J Kreek; J Ott Journal: Neuroscience Date: 2014-11-14 Impact factor: 3.590
Authors: Scott H Kollins; Erin N Schoenfelder; Joseph S English; Alex Holdaway; Elizabeth Van Voorhees; Benjamin R O'Brien; Rachel Dew; Allan K Chrisman Journal: J Subst Abuse Treat Date: 2014-08-07
Authors: Hilary S Connery; Nadine Taghian; Jungjin Kim; Margaret Griffin; Ian R H Rockett; Roger D Weiss; R Kathryn McHugh Journal: Drug Alcohol Depend Date: 2019-10-05 Impact factor: 4.492